- About Us
- Studies for Risk Management
- Consulting on Risk Management
- Other Research Services
- Public Health
- Study Recruitment
The Drug Safety Research Unit (DSRU) is an independent academic unit internationally respected for its work in Pharmacovigilance, Pharmacoepidemiology, Risk Management and Training for over 30 years.
In partnership with doctors in England, the DSRU, led by Director Professor Saad Shakir, aims to protect patients in primary and specialist care from unwanted adverse effects of newly marketed medicines using our unique methods of monitoring patients during the lifecycle of medicines.
Dr Alison Evans, study manager for the ROSE study (Rivaroxaban Observational Safety Evaluation study), is delighted to announce that the 1000th patient has been recruited to the study. The non-interventional post-authorisation study is examining the safety and utilisation of rivaroxaban, a new oral anticoagulant, in secondary care in England and Wales. The study uses the DSRU’s Specialist Cohort Event Monitoring (SCEM) methodology and is supported by a team of regional study facilitators, with assistance from the NIHR Stroke Research Network, Primary Care Research Network and the Non-malignant Haematology and Cardiovascular Speciality Groups.
The study team is grateful to all the NHS Trusts that have recruited to the study so far. Further details about the ROSE study are available here.
Anyone prescribing rivaroxaban or warfarin as per protocol indications can get involved. The ROSE study has one PI in each participating NHS Trust. To check whether your Trust is already active or to enquire about getting your Trust involved please contact us.View our latest news